Skip to main content
. Author manuscript; available in PMC: 2015 May 13.
Published in final edited form as: Cancer Res. 2008 Oct 1;68(19):7811–7818. doi: 10.1158/0008-5472.CAN-08-1320

Table 1.

Metastasis incidence

shControl shControl + Gem ShAGR2-1 shAGR2-1 + Gem
Lung 100% (5/5) 40% (2/5) 100% (5/5) 0% (0/5)*
Liver 100% (5/5) 100% (5/5) 100% (5/5) 60% (3/5)*

NOTE: AGR2 silencing combined with gemcitabine treatment reduces the metastasis incidence in vivo. Tumors were developed in nude mice with MPanc-96 cells stably expressing shControl or shAGR2-1 and also expressing the luciferase gene, and these animals were treated with and without gemcitabine. At the end of the experiment, animals were analyzed by bioluminescence imaging, and the incidence of metastasis was calculated in lung and liver. AGR2 silencing in combination with gemcitabine significantly reduced the lung and liver metastasis incidence. Data shown are mean ± SE for five animals.

Abbreviation: Gem, gemcitabine.

*

P < 0.05 versus control.